key: cord-1049339-obv8aj39 authors: Yang, W.; Shaman, J. title: Epidemiological characteristics of three SARS-CoV-2 variants of concern and implications for future COVID-19 pandemic outcomes date: 2021-05-21 journal: nan DOI: 10.1101/2021.05.19.21257476 sha: 4081e1231735654bf975b0ea30ef07ef3a586e89 doc_id: 1049339 cord_uid: obv8aj39 Three SARS-CoV-2 variants classified as variants of concern - B.1.1.7, B.1.351, and P.1 - have spread globally. To characterize their viral and epidemiological properties in support of public health planning, we develop and apply a model-inference system to estimate the changes in transmissibility and immune escape for each variant, based on case and mortality data from the country where each variant emerged. Accounting for under-detection of infection, disease seasonality, concurrent non-pharmaceutical interventions, and mass-vaccination, we estimate that B.1.1.7 has a 46.6% (95% CI: 32.3 - 54.6%) increase in transmissibility but nominal immune escape from protection induced by prior wild-type infection; B.1.351 has a 32.4% (95% CI: 14.6 - 48.0%) increase in transmissibility and 61.3% (95% CI: 42.6 - 85.8%) immune escape; and P.1 has a 43.3% (95% CI: 30.3 - 65.3%) increase in transmissibility and 52.5% (95% CI: 0 - 75.8%) immune escape. Model simulations indicate that B.1.351 and P.1 could supplant B.1.1.7 dominance and lead to increased infections. Our findings highlight the importance of preventing the spread of B.1.351 and P.1, in addition to B.1.1.7, via continued preventive measures, prompt mass-vaccination of all populations, continued monitoring of vaccine efficacy, and possible updating of vaccine formulations to ensure high efficacy. present -is needed to anticipate future COVID-19 pandemic outcomes and support public 38 health planning. 39 40 In this study, we develop a model-inference system to estimate the relative change in 41 transmissibility and level of immune evasion for different SARS-CoV-2 variants, while 42 accounting for under-detection of infection, delays of reporting, disease seasonality, non-43 pharmaceutical interventions (NPIs), and vaccination. Testing using model-generated synthetic 44 incidence and mortality data indicates this inference system is able to accurately identify shifts 45 in transmissibility and immune evasion. We then apply the validated inference system in 46 conjunction with incidence and mortality data from the UK, South Africa, and Brazil -the three 47 countries where VOCs B. The model-inference system and validation 54 We first tested our model-inference system using 10 model-generated synthetic datasets, 55 depicting different combinations of population susceptibility prior to the emergence of a new 56 variant, changes in transmissibility and immune evasion for the new variant, and infection-57 detection rate. As population susceptibility, interventions, and disease seasonality can all affect 58 apparent transmissibility at a given time and in order to focus on variant-specific properties, 59 here we defined transmissibility as the average number of secondary infections per primary 60 infection, after removing the effects of these three factors (see Methods). We then quantified 61 the change in transmissibility as its relative increase once the new variant becomes dominant. 62 Similarly, we quantify the level of immune evasion as the increase in susceptibility after the 63 new variant becomes dominant, relative to prior population immunity from wild-type infection. 64 65 Fig. 1 shows example test results comparing model-inference system estimates with model-66 generated 'true' values of transmissibility and susceptibility using an infection-detection rate of 67 20%. Across a range of epidemic dynamics, the model-inference system is able to fit both 68 weekly incidence and mortality data (Fig. 1A) and estimate the transmissibility and 69 susceptibility over time for both the initial pandemic wave and the subsequent pandemic wave 70 caused by a new variant (Fig. 1B ). In addition, when aggregated over both pandemic waves, the 71 model-inference system is able to estimate the relative changes in transmissibility and immune 72 evasion due to a new variant (Fig. 1C ). When the system is less well constrained (e.g., an 73 infection-detection rate of 10%), model estimates, albeit less accurate, still closely track true 74 values in most instances ( Fig S1) . 75 efficacy. We focus on NYC for which detailed data and estimates (e.g., contact patterns, variant 151 prevalence, and vaccination rates) are available. Table S1), as has been shown in laboratory studies 7,9 . 166 167 Tallies of model-projected infections ( Fig 4B) and deaths ( Fig S4) reveal four key determinants 168 of future pandemic outcomes. First, simultaneous introduction of both the B.1.351 and P.1 169 variants would lead to larger increases of infections and mortality than sole introduction of 170 either variant (Fig 4B and Fig S4B) . This result indicates the importance of limiting the 171 introduction of multiple VOCs. Second, maintaining very high vaccine efficacies against all 172 variants is critical for mitigating the risk of a large resurgence in populations with relatively high 173 vaccination coverage (e.g., compare the first three subplots in Fig 4B) . Third, continued non-174 pharmaceutical preventive measures will reduce infection resurgence as municipalities reopen 175 economies. For instance, even with high vaccine efficacy, a rapid, full reopening before a very 176 large proportion of the population are fully vaccinated could lead to approximately three times 177 as many infections as when reopening occurs more slowly (Fig 4A and Fig 4B first subplot) . Four, 178 reassuringly, while projected trends for COVID-19-related mortality are in general similar to 179 those for infection ( Fig S4A vs. Fig 4A) , lower proportions of COVID-19-related deaths would 180 occur due to the increased transmission of B.1.351 and/or P.1 (Fig S4B vs. Fig 4B; note the 181 larger proportion of deaths due to B.1.1.7 than infections). This is due to the currently higher 182 vaccination coverage among older adults who have been prioritized for vaccination in NYC 183 similar to many other municipalities (see Table S4 3, 4 and little immune evasion based on laboratory and real-world vaccination data 5, 6, 15 Our model-inference system estimates substantial immune escape for both P. 1 and B.1.351. 212 For P.1, the mean estimate is bounded by a very broad confidence interval; however, for 213 B.1.351 the uncertainty is more constrained and indicates greater confidence that a substantial 214 level of immune escape occurs. These latter findings are supported by vaccine clinical trial and 215 real-world data. In particular, Shinde et al. 13 found a similar likelihood of COVID-19, mostly due 216 to B.1.351, among trial participants who were seropositive at enrollment (i.e., after the first 217 wave) compared to those seronegative. Although potential differences in risk of exposure 218 among the two comparison groups may have somewhat biased this finding, substantial repeat 219 and breakthrough infection occurred due to B. highlights the importance of full vaccination (i.e., administration of both doses for mRNA 225 vaccines), as participants gained little protection against severe illness after the first vaccine 226 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 dose (vs. ~50% efficacy for B.1.1.7), even though full protection against severe illness was 227 retained after two vaccine doses. It is thus likely critical that best vaccination protocols are 228 followed in order to confer protection against variants with immune escape properties and that 229 potential waning of vaccine-induced immunity over time is monitored. 230 231 In light of the spatial expansion of B. Due to a lack of sub-regional data, we used aggregated country-level data to estimate the 243 properties for the three VOCs. Our model-inference system also did not account for differences 244 of disease severity and infection-detection rate among age groups, which may vary 245 substantially. 17 This model simplification may introduce uncertainty and bias to our estimates, 246 particularly for Brazil where country-level data may mask more intense transmission in 247 subpopulations and may have led to underestimation of the transmissibility of P. 1. 248 Nevertheless, validation using independent data, including for Brazil, indicates that the model-249 inference system is able to closely capture pandemic dynamics and accurately estimate 250 cumulative infection rates (Fig 2) . Further, because the model-inference system simultaneously 251 accounts for population susceptibility, disease seasonality, NPIs, and vaccination, it is able to 252 specifically estimate changes related to a given new variant and closely matches available 253 epidemiological data (e.g., for B. mathematically because the product of these two quantities, rather than either individually, 295 determines disease incidence -i.e., at any point in time, given the incidence, transmissibility 296 and susceptibility are not individually identifiable. Nevertheless, we posit that transmissibility 297 and susceptibility affect epidemic dynamics differentially over time, and, as such, data at 298 multiple time points can enable joint estimation. We thus design a model-inference system to 299 estimate the most plausible joint changes in these two quantities using commonly available 300 incidence and mortality time series. 301 302 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 The model -inference system is comprised of an epidemic model for simulating the transmission 303 dynamics of SARS-CoV-2 and a statistical inference method for estimating the model state 304 variables and parameters. The epidemic model is a susceptible-exposed-infectious-recovered-305 susceptible (SEIRS) construct that further accounts for two-dose vaccination. In addition, to 306 include the effects of public health interventions and disease seasonality, it further adjusts the 307 transmission rate each week using mobility data and the estimated seasonal trend based on 308 climate conditions (see Eqn S3 in the Supplemental Information). The system then combines 309 the model-simulated (prior) estimates and observed case and mortality data to compute 310 posterior estimates using the ensemble Kalman adjustment filter (EAKF). 29 We also apply a 311 technique termed space re-probing 30 that accommodates possible large changes mid-pandemic 312 to transmissibility and population susceptibility. Further, due to the challenge identifying these 313 two quantities individually, we ran the model-inference system, repeatedly and in turn, in order 314 to test 14 major combinations of changes in transmissibility and susceptibility (see details in 315 Supplemental Information). Briefly, depending on the hypothesized change, we restricted the 316 EAKF update to a given related set of parameters or variables. For instance, for the hypothesis 317 that the new variant changes the transmissibility but does not evade immunity, the system only 318 allows major adjustment to the transmission rate and the infectious period; for the hypothesis 319 that the new variant induces both changes, the system allows major adjustment to the 320 transmission rate, the infectious period, and population susceptibility. The system then selects 321 the run with the best performance based on the accuracy of model-fit, one-step ahead 322 prediction, and magnitude of changes to key state variables to identify the most plausible 323 combination of changes in transmissibility and level of immune evasion (see Supplemental 324 Information). To approximate the distribution of the system (including all model state variables 325 and parameters), we employed an ensemble of model replica (n = 500 here) and updated the 326 ensemble posterior each week using the EAKF. In addition, to account for model stochasticity, 327 we repeated each model-inference simulation 100 times for each dataset, each with initial 328 parameters and variables randomly drawn from prior distributions (Table S2) . Consequently, 329 model estimates are aggregated from 50,000 model runs in total. 330 331 Estimation of variant-specific changes in transmissibility and level of immune evasion 332 The model decouples the impact of concurrent NPIs and disease seasonality from the 333 transmission rate and infectious period (Eqn S3); as such, estimates for the latter two 334 parameters are variant-specific. We thus compute transmissibility as the product of the 335 transmission rate and infectious period. To reduce uncertainty, we average transmissibility 336 estimates over the first pandemic wave (excluding the first three weeks when model estimates 337 are less accurate) for the wild-type SARS-CoV-2 virus; similarly, we average the transmissibility 338 estimates over the period when the new variant is dominant. We identify this latter time period 339 based on the transmissibility estimates: 1) For the UK (B.1.1.7) and South Africa (B.1.351), the 340 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.19.21257476 doi: medRxiv preprint estimated transmissibility increased and plateaued within 10 weeks (see Fig 3) ; we thus used 341 the period from the week with the maximal transmissibility during the 10 weeks following its 342 initial increase to the end of our study period (i.e., the week of 4/11/2021). However, for the 343 UK, we excluded the 3 rd lockdown period when estimated transmissibility is lower, potentially 344 due to better awareness of B. 2) For Brazil (P.1), the estimated transmissibility increased more gradually (see Fig 3) , we thus 349 instead used either the weeks identified per 1) or the last 8 weeks of our study period, 350 whichever with a longer time period, to ensure the robustness of estimation. We then 351 compute the average change in transmissibility due to a new variant as the ratio of the two 352 averaged estimates (i.e., after: before the rise of the new variant). 353 354 To quantify immune evasion, we record all time points inducing major EAKF adjustments to 355 posterior estimates of susceptibility, compute the change in immunity as ΔImm = St+1 -St + it 356 (with St as the susceptibility at time-t and it as the new infections occurring at time-t), and sum 357 over all ΔImm estimates to compute the total change in immunity due to the new variant. We 358 then compute the level of immune evasion as the ratio of the total change in immunity during 359 the second wave to the model-estimated population immunity at the end of the first wave. This 360 ratio provides an estimate of the fraction of individuals previously infected who are susceptible 361 to re-infection with the new variant. 362 363 For both quantities, we report the mean and 95% CI based on the mean estimates from 100 364 repeated model-inference runs. Model validation using model-generated synthetic data 367 To test the accuracy of the model-inference system, we generated 10 synthetic datasets using a 368 two-variant SEIRS model (see Eqn. S4) and different scenarios of changing transmissibility and 369 immune evasion (Table S3 ). In each scenario, a new variant was introduced at week 21 of the 370 simulation. We then combined the incidence and mortality due to both variants and added 371 noise drawn from a Poisson distribution to represent observational error. We then applied the 372 model-inference system to estimate the model variables and parameters for each synthetic 373 dataset, per the procedure described above for real data. For comparison with model-374 inference system estimates, we computed the true values of population susceptibility and 375 transmissibility over time as the weighted average of the two variants based on the relative 376 prevalence at each time point (i.e., each week). 377 378 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. between each pair of SARS-CoV-2 variants (e.g. wild-type and B.1.1.7) via cross-protective 400 immunity; 2) variant-specific transmissibility and population susceptibility, based on estimates 401 derived in this study; 3) variant-specific vaccine efficacy under different scenarios (see Table 402 S5); 4) age-specific differences in vaccination coverage at the start of simulation and 403 vaccination uptake rates for the simulation period (see Table S4 ); 5) seasonality; and 6) changes 404 in NPIs under different scenarios (see Table S5 ). We used data from NYC for baseline 405 vaccination coverage 32 and initial prevalence of different variants, 33 as well as key model 406 estimates (e.g., transmission rates and infection fatality risk by age group; see Table S5 ) 17,34,35 . 407 As in previous work, 17,34,35 we included 8 age-groups (i.e. <1, 1-4, 5-14, 15-24, 25-44, 45-64, 65-408 74, and 75+ year-olds) relatively minor). We did not account for potential differences in infection fatality risk by 415 variant, as such information is not available; therefore, the simulated mortality under different 416 scenarios only reflect the relative infection rate by age group, for which we apply age-specific 417 infection-fatality risk (see Table S5 ). In addition, due to uncertainty vis-à-vis the severity and 418 infection fatality risk among breakthrough infections (i.e., those who have been vaccinated), we 419 only show mortality-related simulations for the "Same VE" scenario which assumes no 420 reduction in VE. 421 422 Data Availability: All data used in this study are publicly available as described in the "Data 423 sources and processing" section. 424 425 Code availability: All source code and data necessary for the replication of our results and 426 figures will be made publicly available. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.19.21257476 doi: medRxiv preprint cases (in blue) and deaths (in red) per 1 million persons; boxes and whiskers show corresponding model estimates (mean, 50% and 95% CrIs). Grey shaded boxes indicate the timing of lockdowns or key periods of restricted activity; horizontal arrows indicate the timing of variant identification and vaccination rollout. The right column compares available, independent measurements to corresponding model estimates. Red dots and error bars show measured prevalence over 10 periods of time from the REACT study for the UK (B), cumulative infection rates from two serology studies in South Africa (D), and cumulative infection rates from two nationwide household serosurveys in Brazil (F). Blue lines and surrounding areas show model estimated mean, 50% (dark) and 95% (light) CrIs. Key model-inference system estimates. Left column shows estimated real-time reproduction number Rt, middle column shows estimated transmissibility, and right column shows estimated population susceptibility for each week during the study period, for the three countries. For comparison, estimated weekly infection rates are superimposed in each plot (right y-axis). Blue lines and surrounding areas show the estimated mean, 50% (dark) and 95% (light) CrIs. Boxes and whiskers show the estimated weekly infection rates (mean, 50% and 95% CrIs). Grey shaded areas indicate the timing of lockdowns or key periods of restricted activity; horizontal arrows indicate the timing of variant identification and vaccination rollout. Note that the transmissibility estimates (middle column) have removed the effects of changing population susceptibility, NPIs, and disease seasonality; thus, the trends are more stable than the reproduction number (Rt; left column) and reflect changes in variant-specific properties. Tallies over the entire simulation period (May -Aug 2021) for different scenarios of seeding, VE (as indicated in the subtitles), and NPIs (as indicated by the x-axis labels). All numbers are scaled for 1 million people. For the projected percentages for each variant and uncertainty bounds, see Table S1 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Relative change (%) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Model-inference system fit to data for the three countries and validation using independent datasets. The left column shows the model fit to reported weekly case and mortality data for the UK (A), South Africa (C), and Brazil (D). Dots show the weekly number of cases (in blue) and deaths (in red) per 1 million persons; boxes and whiskers show corresponding model estimates (mean, 50% and 95% CrIs). Grey shaded boxes indicate the timing of lockdowns or key periods of restricted activity; horizontal arrows indicate the timing of variant identification and vaccination rollout. The right column compares available, independent measurements to corresponding model estimates. Red dots and error bars show measured prevalence over 10 periods of time from the REACT study for the UK (B), cumulative infection rates from two serology studies in South Africa (D), and cumulative infection rates from two nationwide household serosurveys in Brazil (F). Blue lines and surrounding areas show model estimated mean, 50% (dark) and 95% (light) CrIs. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Tallies over the entire simulation period (May -Aug 2021) for different scenarios of seeding, VE (as indicated in the subtitles), and NPIs (as indicated by the x-axis labels). All numbers are scaled for 1 million people. For the projected percentages for each variant and uncertainty bounds, see Table S1 . Fast full reopen, equal seeding Fast full reopen, more P. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Epidemiological characteristics of three SARS-CoV-2 variants of concern and implications for 3 future COVID-19 pandemic outcomes 4 Wan Yang and Jeffrey Shaman 5 6 Many respiratory infections tend to occur seasonally and are predominantly prevalent during 8 certain months of the year (e.g., cold months in temperate climates). 1 This seasonal pattern has 9 been documented for influenza viruses, 2 respiratory syncytial viruses, 3 and endemic human 10 coronaviruses. 4 In addition, studies have showed that this seasonality may be associated with 11 climate conditions -particularly, temperature and humidity -as they may modulate the 12 survival and transmission of respiratory viruses. [5] [6] [7] [8] For the SARS-CoV-2 virus, our work has also 13 shown that a winter-time seasonality exists, similar to endemic human coronaviruses in New 14 York City (NYC), and that models accounting for this seasonality enable more accurate 15 projection of COVID-19 pandemic dynamics than those do not. 9,10 However, to date, no 16 mechanistic models exist that quantify the response of the SARS-CoV-2 virus to temperature 17 and humidity and in turn the seasonality of COVID-19. In addition, seasonal trends may differ by 18 climate. For instance, epidemics of influenza can occur any time of the year in subtropical and 19 tropical climates; it is thus more difficult to characterize the seasonality of respiratory infections 20 in these climates. To address these challenges, we recently developed a flexible climate-forced 21 model of epidemic dynamics for subtropical and tropical climates; results with this model also 22 describe the response to temperature and humidity conditions common in temperate 23 climates. 11,12 Thus, to account for the potentially diverse seasonal trends of COVID-19 in the 24 UK (temperate climates), South Africa (mostly temperate climates), and Brazil (mostly tropical 25 climates), we applied this climate-forcing to temperature and humidity data for each country 26 and computed the relative seasonal trend for each country. 27 28 Specifically, the climate-forcing takes the following form: 29 where R0(t) is the basic reproduction number at time t; q(t) is specific humidity (i.e. a measure 30 of absolute humidity) at time t; and T(t) is temperature at time t. In essence, the forcing 31 function assumes that specific humidity has a bimodal effect on R0, with both low and high 32 humidity conditions favoring transmission; in addition, this effect is moderated by temperature, 33 where low temperatures promote transmission and temperatures above a certain threshold 34 (i.e., Tc in Eqn. S1) limit transmission. Further, to link the coefficients a, b, and c to humidity q 35 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. between the maximum and minimum R0), qmin, qmid, and qmax (i.e., the minimum, median, and 41 maximum specific humidity for the response), Tc (the threshold temperature) and Texp (the 42 exponent in Eqn S1) for influenza in Hong Kong, a subtropical city, based on long-term epidemic 43 data collected therein during 1998 -2018. Here we use their mean estimates for these 44 parameters and temperature and humidity data for each country (see main text and Fig S5) to 45 compute the seasonal trend for each country using Eqns. S1-2. However, as these parameters 46 were estimated for influenza, the outputs do not represent the actual R0 for the SARS-CoV-2 47 virus. Thus, we instead compute the relative seasonal trend, by scaling the weekly country 48 output from Eqn S1 by the country mean output, such that this scaled output provides a 49 relative, seasonality-related transmissibility for each week of the year (see results in Fig S2) . 50 These relative estimates also decouple the seasonality-related and variant-specific 51 transmissibility (assuming no interaction; see below). 52 53 The model-inference system developed for this study consists of an SEIRSV model to simulate 55 the transmission dynamics of SARS-CoV-2 and the ensemble Kalman adjustment filter (EAKF) 13 56 to estimate the model state variables and parameters, based on case and mortality data. Here 57 we describe the model and the filtering method in detail. 58 59 2.1. Epidemic model. 60 The SEIRSV (susceptible-exposed-infectious-recovered-susceptible-vaccination) model uses the 61 following set of equations to simulate the transition of sub-populations between different 62 disease stages, while accounting for disease seasonality, concurrent non-pharmaceutical 63 interventions (NPIs), and vaccination: 64 65 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. where S, E, I, R are the number of susceptible, exposed (but not yet infectious), infectious, and 67 recovered/deceased individuals, respectively; N is the population size. The parameter ε 68 represents travel-related importation of infections (nominally set to 1 per 20 days per 1 million 69 population, unless specified otherwise). To account for local seasonality, bt, the estimated 70 relative seasonal trend for each country (see Section 1 above and Fig S2) is used to adjust the 71 relative transmission rate at time t. To account for concurrent NPIs, the term mt, the relative 72 population mobility at time t (in this study, we use data from Google Community Mobility 73 Reports; 14 see main text and Fig S2) , is used to adjust the transmission rate. In addition, as the 74 effectiveness of NPIs is unknown and variable, the model further includes a parameter, et, to 75 scale NPI effectiveness at time t. For virus-specific characterization, N K is the variant-specific 76 transmission rate at time t, Z is the latency period, D is the infectious period, and L is the 77 immunity period. Note that the parameters et, N K , Z, D, and L are estimated by the model-78 inference system as described below. 79 80 To incorporate changes in population susceptibility due to vaccination, the model accounts for 81 two-dose vaccination via v1(t) and v2(t). Specifically, v1(t) is the number of individuals 82 successfully immunized after the first dose of the vaccine and is computed using vaccination 83 data and vaccine efficacy for 1 st dose (see detailed settings in infectiousness to detection (i.e., an infection being diagnosed as a case) -drawn from a gamma 91 distribution with a mean of Tm and standard deviation (SD) of Tsd days -to account for delays in 92 diagnosis and detection; 2) an infection-detection rate (r), i.e. the fraction of infections 93 (including subclinical or asymptomatic infections) reported as cases, to account for under-94 detection; 3) a time-lag from infectiousness to death, drawn from a gamma distribution with a 95 mean of 14 days and a standard deviation of 10 days, empirically based on mortality data; and 96 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. At the end of each week, the inference system uses the EAKF to update the state variables and 111 parameters based on model-generated prior estimates and case and mortality data. Briefly, the 112 EAKF uses an ensemble of model realizations (n=500 here), each with initial parameters and 113 variables randomly drawn from a prior range (see Table S2 ). After model initialization, the 114 system integrates the model ensemble forward in time for a week (per Eqn S3) stochastically to 115 compute the prior distribution for each model state variable or parameter, as well as the 116 model-simulated number of cases and deaths for that week as described in Section 2.2. The 117 system then combines the prior estimates with the observed case and death data for the same 118 week to compute the posterior per Bayes' theorem. 13 During this filtering process, the system 119 updates the posterior distribution of all model parameters and variables for each week. 13 As 120 such, it is able to capture the time-varying changes in transmission dynamics including the 121 variant-specific transmission rate (N K ) and infectious period (D) -the two parameters that we 122 use to compute variant-specific transmissibility over time. 123 124 However, unlike previous studies using similar model-inference approaches, here we further 125 modify the EAKF filtering process to test different potential combinations of changes in 126 transmissibility and immune escape. To enable this exploration of systemic changes (e.g. due 127 to the emergence of a new variant), we randomly replace a small fraction of ensemble 128 members (3-10%) using values randomly drawn from specified ranges. This technique, termed 129 space reprobing (SR), was developed in order to explore state space without corrupting 130 performance of the filter. 15 Specifically for this application, we apply SR to a given related set of 131 parameters/variables and restrict the EAKF update of non-related parameters/variables, for 14 132 different hypothesized behaviors. These hypothesized changes are as follows: 133 134 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. only allowed for the two transmissibility-related parameters N K and D; to explore the 136 changes, the system applies SR to these two parameters using values drawn from prior 137 ranges 10-20% higher than the initial priors. 138 2) Hypothesis 2 (major changes in transmissibility only, no immune escape): Similar to 1); 139 but to explore the changes, the system applies SR to N K and D using values drawn from 140 prior ranges 30-40% higher than the initial priors. To explore 157 the changes, initial SR uses values drawn from prior ranges 10-20% higher than the 158 initial priors, and values up to 30-40% higher than the initial priors if the inference 159 system detects the prior continues to underestimate the observed cases and deaths 160 with the 10-20% initial increase in SR values. In addition, SR allows updates of S up to 161 95% of the prior immunity. 162 163 To account for slower changes in overall population immunity (i.e., in the entire country) as the 164 new variant gradually spreads to different sub-regions across a large geographic space, such as 165 in Brazil, we also explore the fitting using the following five additional settings: 166 167 10) Hypothesis 10 (immune escape only and changes to overall population immunity occur 168 slowly over time): Large updates are only allowed for S, up to a total loss of 95% of the 169 prior immunity; however, SR is applied to a smaller fraction of ensemble members than 170 in 1)-9) such that changes in S occur gradually. 171 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 11) Hypothesis 11 (minor changes in transmissibility + minor immune escape; both occur 172 slowly over time): Large updates are allowed for N K and D as well as S. Adjustment to S 173 is allowed as in 10) but up to only 50% of prior immunity. In addition, for 174 transmissibility, the system applies SR to N K and D using values drawn from prior ranges 175 10-20% higher than the initial priors. 176 12) Hypothesis 12 (major changes in transmissibility + minor immune escape; both occur 177 slowly over time): Similar to 11); however, for N K and D, initial SR uses values drawn 178 from prior ranges 10-20% higher than the initial priors, and values up to 30-40% higher 179 than the initial priors if the inference system detects the prior continues to 180 underestimate the observed cases and deaths with the 10-20% initial increase in SR 181 values. 182 13) Hypothesis 13 (minor changes in transmissibility + major immune escape; both occur 183 slowly over time): Similar to the settings specified in 11) but adjustment to S is allowed 184 up to 95% of prior immunity. 185 14) Hypothesis 14 (major changes in transmissibility + major immune escape; both occur 186 slowly over time): Similar to settings specified in 12) but adjustment to S is allowed up 187 to 95% of the prior immunity. 188 189 We carry out the model-inference process for each of the 14 settings described above and for 190 each country dataset. We then select the most plausible hypothesis for each country based on 191 the following criteria: 1) model fitting to case and mortality data, as indicated by the relative 192 root-mean-squared-error (RRMSE) between the posterior estimates for the corresponding 193 variable (i.e. case rate or mortality rate) and data; 2) the accuracy of one-step ahead prediction, 194 as indicated by the RRMSE between the prior estimates for the corresponding variable (i.e. case 195 rate or mortality rate) and data; 3) the level of adjustment needed for two key variables, i.e., 196 infection rate and case rate, as indicated by the RRMSE between the prior and posterior 197 estimates for each variable; 4) a penalty on the number of variables needing SR adjustment; 198 and 5) a penalty on the frequency of SR adjustment. We combine all these metrics by weighting 199 them heuristically using the following set of weights: 0.27 for the two metrics in 1); 0.13 for the 200 two metrics in 2), 0.03 for the two metrics in 3), and 0.07 for both 4) and 5). We also tested 201 other sets of weights and found that higher weights should be given to 1) and 2) based on 202 results from the synthetic testing where the 'true' values of the state variables and parameters 203 are known; however, in general, the final results are similar if there are minor changes to these 204 weights. To account for model stochasticity, we repeat each model-inference 100 times for each 207 dataset, each with initial parameters and variables randomly drawn from the prior distributions 208 (Table S2) . Each model-inference tests the 14 hypotheses described above, selects the one with 209 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 the best performance (i.e. minimizing the combined metric described above), and outputs the 210 estimates of the best-performing run. That is, the model estimates reported in the main text 211 are aggregated from 100 best-performing model runs (each with 500 ensemble members and 212 totaling 50,000 individual model realizations). 213 214 To test the accuracy of our model-inference system, we generate 10 synthetic datasets using a 216 separate multi-variant SEIRS model, similar to models developed in Yang et al. 16 and Gog & 217 Grenfell. 17 Within this model, variants can interact via cross-immunity, which protects a 218 portion of individuals with prior infection (i.e. polarized immunity) by reducing transmission. 219 Specifically, the model takes the following form: 220 221 where N is the population size; Si, Ei, Ii, and Ri, are, respectively, the numbers of susceptible, 223 exposed-but-not-yet infectious, infectious, and recovered individuals, with respect to variant-i 224 (here, the wild-type SARS-CoV-2 virus or a new variant); N = , Di, and Li are, respectively, the 225 transmission rate, mean infectious period, and mean immunity period, for variant-i; and cij 226 measures the strength of cross-immunity to variant-i conferred by infection with variant-j (e.g., 227 close to 0 if it is weak and cii=1 for infection by the same variant). The parameter ε represents 228 travel-related importation of infections; to generate the synthetic data (i.e., "truths"), we set ε 229 to 1 per week for the first 5 weeks and 1 every 3 days for the rest of the first wave (here weeks 230 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ; for the second wave, as transmission has been established locally, we set ε to 0 for 231 simplicity. The terms bt, mt, and et are the same as in Eqn S3 and account for seasonality and 232 NPIs over time. For simplicity, we omit birth, death, and vaccination. 233 234 To generate the synthetic data (i.e., "truths"), we seed the Eq. S4 model with 2 infections of 235 wild-type virus at the start of each simulation and 50 infections of a new variant at the start of 236 Week 21, for N = 1 million people; we run the model stochastically with a daily time-step from 237 the week starting 3/1/2020 to the week starting 2/21/2021 (i.e. 52 weeks in total) using the 238 parameters listed in Table S3 . To compute the weekly number of cases and deaths, we use the 239 same procedure as described in Section 2.2 above for each variant. We then combine the 240 case/mortality estimates for both variants, add random noises drawn from a Poisson 241 distribution to mimic observational error. The final noise-added weekly case and mortality time 242 series are then used as synthetic data for testing the model-inference system (described in 243 Section 2 above). To compare the posterior estimates of key parameters and variables (e.g. 244 transmissibility and population susceptibility) from the model-inference system, we compute 245 the true values of population susceptibility and transmissibility over time as the weighted 246 average of the two variants based on the relative prevalence during each week. Fig 1 and Fig S1 247 show the 10 model-generated truths including cases, deaths, and the computed "true" values 248 of population susceptibility and transmissibility for each week of the simulation. 249 250 VOCs and project future SARS-CoV-2 dynamics. 252 We modify the multi-variant model in Eqn S4 to further include age structure and vaccination. 253 The inclusion of age structure here allows incorporation of age-specific parameters (e.g., 254 transmission rate and infection-fatality risk) as well as age-specific vaccination coverage and 255 rates. Specifically, this multi-variant, age-structured SEIRSV model takes the following form: 256 Model parameters in Eqn S5 are similar to those in Eqn S4, expect for those related to age, 258 which are indicated by the superscripts. The vaccination model component is also similar to 259 Eqn S3, but with age-stratification. However, the terms R =,S Y ($) and R =,* Y ($) are variant-specific, 260 as indicated by the additional subscript i; that is, they additionally account for the reduction in 261 vaccine efficacy against the new variants, based on scenario assumptions specified in Table S5. 262 263 As an example, we simulate the transmission dynamics under different scenarios of variant 264 prevalence, vaccine efficacy, and NPIs for a city like NYC, from the week of 4/25/2021 to the 265 week of 8/22/2021 (i.e., approximately May -August 2021). We use data or estimates available 266 for NYC to initialize the parameters and state variables needed for model simulations. In 267 addition, we use our model-inference estimates for the VOCs for related parameters and 268 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 variables. Specifically, as in previous work, 9,10,18 we include 8 age-groups (i.e. <1, 1-4, 5-14, 15-269 24, 25-44, 45-64, 65-74, and 75+ year-olds) to account for age-specific differences. To focus on 270 the three VOCs, here we only include the B.1.1.7, B.1.351, and P.1 variants and attribute the 271 rest as "wildtype" virus. NYC data on variant prevalence among tested infections during the 272 weeks of March -April 2021 are used to inform the initial range of seeding for each variant 273 (Table S5 ). Initial conditions for the state variables (e.g., susceptibility and SARS-CoV-2 274 prevalence) for each age group are taken from estimates 9,10,18 made for the week of 4/18/2021, 275 using detailed data (including case, mortality, COVID-19-related emergency visit, mobility, and 276 vaccination) during 3/1/2020 -4/24/2021. For each age group, to compute the initial variant-277 specific population susceptibility (Si) at the start of a simulation, we move the estimated 278 proportion with immune escape for variant i among those who have had prior infection with 279 the wild-type virus but have not been vaccinated back to the susceptible compartment. The 280 number of people losing vaccine-induced immunity is computed based on scenario assumptions 281 determining the reduction in vaccine efficacy (see scenarios in Table S5 ). 282 283 The cross-immunity settings, i.e., values of cij's in Eqn S5, come from our posterior model-284 inference estimates of immune escape and are used for all age groups. To reduce uncertainty, 285 here we use the 80% CI estimates (see Table S5 ). Due to a lack of information, we do not account for potential differences in infection fatality 300 risk by variant; therefore, the simulated mortality under different scenarios only reflect the 301 relative infection rate by age group, for which we apply age-specific infection-fatality risk (see 302 Table S5 ). In addition, due to the uncertainty of the infection fatality risk among breakthrough 303 infections (i.e., those who have been vaccinated), we only show mortality-related simulations 304 for the "Same VE" scenario which assumes no reduction in VE. 305 306 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 We run the model for each scenario 1000 times stochastically, with the parameters and initial 307 conditions randomly drawn from uniform distributions with ranges specified in Table S5 . 308 Results are summarized from the 1000 model runs for each scenario. 309 310 Fig S1. Model validation using model-generated synthetic data with an infection-detection rate set to 10%. (A) 5 sets of synthetic data (dots) and model-fits to each dataset; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs. (B) weekly model estimated transmissibility and population susceptibility; lines show mean estimates and surrounding areas show 50% (dark) and 95% (light) CrIs, compared to the true values (dots). (C) overall estimates of the change in transmissibility and immune evasion (boxes and whiskers show model estimated median, interquartile range, and 95% CI from 100 model-inference simulations) compared to the true values (dots). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Relative mobility / Estimated Seasonal trend All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Fig S4. Model projections of COVID-19 related mortality under different scenarios of VOC cocirculation and NPI. Due to the uncertainty on the infection fatality risk among breakthrough infections (i.e., those who have been vaccinated), all simulations shown here assume no reduction in vaccine efficacy (VE). All numbers are scaled for 1 million people. Fast full reopen, equal seeding Fast full reopen, more P. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Infectiondetection rate 20% for results shown in Fig 1 and 10% for results shown in Fig S1. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S4 . Cumulative vaccination coverage used in the multi-variant, age-structured model simulations. Baseline vaccination coverage (as of 4/24/2021) is based on data for NYC. Projected vaccination rates for the simulation period (from the week starting 4/25/2021 to the week ending 8/29/2021) are based on data 10 days preceding the simulation and assuming a cumulative vaccination uptake of 80%. Note that ages under 15 (i.e., <1, 1-4, 5-14 years) are combined in the same column as they were not eligible to receive the vaccines at the time of this study. In addition, the numbers are aggregated from neighborhood-level estimates and thus could slightly exceed the 80% total for some age groups when some neighborhoods had actual vaccination coverage above 80% at baseline. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101/2021.05.19.21257476 doi: medRxiv preprint Table S5 . Parameter settings for different scenarios to simulate and project the impact of different variants of concern. Initial conditions and parameters are randomly drawn from uniform distributions with lower and upper bounds as specified below, based on estimates for NYC made for the week of 4/18/2021 using data during 3/1/2020 -4/24/2021. Numbers associated with the parameter names denote the corresponding age groups. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 An Ensemble Adjustment Kalman Filter for Data Assimilation 1 Fully open 1 Fully open 1 Fully open 1 Fully open 351 Current NPI High VE Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. The Lancet. Infectious diseases A simple modification for improving inference of non-linear dynamical systems Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet. Infectious diseases